Jeffrey Friedman MD

Jeffrey Friedman MD General Information

Biography

Dr. Jeffrey Friedman is the Founder and serves as Managing Partner at Friedman BioVentures. He serves as a Board Member at TRIO Pharmaceuticals. He served as a Board Member & Scientific Advisor at DTx Pharma. He served as a Board Member at PetDx. He also serves as a Board Member at MatriSys Bioscience. He serves also as a Board Member at PetDx. He also served as a Board Member at Celsense. He previously served as a Board Member at Pediatric Bioscience. He served as an Advisor at Nasseo. After receiving a BS in biology from MIT, Jeff earned an MD and Ph.D. in Cancer Biology with Irv Weissman at Stanford University. His thesis elucidated the mechanism of action of the immunosuppressive drugs cyclosporine A and FK506. He went on to train in Pediatrics at Boston Children's Hospital and was a fellow in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute. From 2003-2012 he was a Principal Investigator at the Scripps Research Institute (La Jolla, CA) studying red cell and bone marrow disorders. Currently, he oversees a mixed portfolio of private and public companies in the biotechnology and pharmaceutical space, with an emphasis on platform technologies, oncology, and genomics. In addition to serving as a Series A Director of Pediatric Bioscience on behalf of Tech Coast Angels, he also serves on the board of Cypher Genomics, a startup that provides an analysis of next-generation sequencing data. He also is Chair of the Research Committee and a board member of CurePSP, a nationwide foundation funding research and providing education and support to patients with Progressive Supranuclear Palsy (PSP) and to their families and caregivers.